Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00896337 · ClinicalTrials.gov registry record · Phase 3
EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries
A Phase 3 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
NCT00896337: Completed Phase 3 study, sponsored by Boston Scientific Corporation.
NCT00896337 is a Phase 3 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 125 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00896337, a Phase 3 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
Study Summary
The ORION study is being conducted to determine whether the Epic™ Nitinol Stent for primary stenting of iliac atherosclerotic lesions shows acceptable performance at 9 months.
Primary Outcome
MAE is defined as any device-related or index procedure-related death within 30 days, myocardial infarction during index hospitalization, target vessel revascularization through 9 months, or amputation of the index limb through 9 months
Interventions
- DEVICE Epic™ Nitinol Stent System
- DRUG Anti-platelet therapy
- DRUG Anti-coagulation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2009-05 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
What the finished NCT00896337 record still lists
NCT00896337 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 3 interventions - of which Epic™ Nitinol Stent System is the first listed.
NCT00896337 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00896337 about?
NCT00896337 is a clinical study titled "EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries". The ORION study is being conducted to determine whether the Epic™ Nitinol Stent for primary stenting of iliac atherosclerotic lesions shows acceptable performance at 9 months.
What is the current status of trial NCT00896337?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2009-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00896337?
The interventions under investigation include: Epic™ Nitinol Stent System (DEVICE), Anti-platelet therapy (DRUG), Anti-coagulation therapy (DRUG).
Who is sponsoring clinical trial NCT00896337?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00896337's enrollment target sits among peer trials
125 1605th of 2000 higher than 391 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia